ProfileGDS5678 / 1453485_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 74% 72% 73% 71% 73% 72% 74% 71% 71% 72% 73% 65% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4640371
GSM967853U87-EV human glioblastoma xenograft - Control 24.8379774
GSM967854U87-EV human glioblastoma xenograft - Control 34.5582172
GSM967855U87-EV human glioblastoma xenograft - Control 44.8033273
GSM967856U87-EV human glioblastoma xenograft - Control 54.4497371
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5848973
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5533472
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7619674
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.5302371
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4543371
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5393972
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7914273
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9507265
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.525172